Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lantern Pharma ( (LTRN) ) is now available.
On May 12, 2026, Lantern Pharma entered into a securities purchase agreement with institutional investors for a registered direct offering of common shares and pre-funded warrants, which closed on May 14, 2026 and generated approximately $4.4 million in gross proceeds for working capital and general corporate purposes. In a concurrent private placement, the company issued additional warrants, granted investors participation rights in future equity financings of a planned AI-focused subsidiary built around withZeta.ai, imposed a two-year ban on variable-rate financings, suspended use of its existing at-the-market facility, and outlined plans to separate its AI platform into an independently financed, potentially exchange-listed business under CEO Panna Sharma, aiming to unlock distinct valuation and strategic flexibility for stakeholders.
On May 13, 2026, Lantern Pharma also detailed warrant economics, placement-agent compensation, and investor ownership caps designed to limit immediate dilution while leaving open up to $4.85 million in potential future proceeds from warrant exercises. The move signals an effort to shore up liquidity for its oncology pipeline while positioning its withZeta.ai technology as a standalone AI co-scientist platform for investors and biotech executives, potentially enhancing the company’s industry positioning at the intersection of AI and drug development.
The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and ongoing cash burn). Technicals also weigh on the rating given the stock’s position below key moving averages. Valuation is only a modest offset because the negative P/E is not informative and there is no dividend support.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc. is a clinical-stage, AI-driven precision oncology company listed on Nasdaq that focuses on transforming the cost and pace of oncology drug discovery and development. Its proprietary RADR platform, deployed through withZeta.ai, applies machine learning to vast oncology datasets to identify biomarker signatures and advance small-molecule and antibody-drug conjugate candidates for hard-to-treat solid and hematologic cancers.
Average Trading Volume: 617,283
Technical Sentiment Signal: Sell
Current Market Cap: $23.29M
For an in-depth examination of LTRN stock, go to TipRanks’ Overview page.